Dashboard
Manage Tickers

DVAX DYNAVAX TECHNOLOGIES CORP

Nasdaq dynavax.com


$ 10.55 $ -0.43 (-3.92 %)    

Friday, 07-Nov-2025 10:42:36 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 602.77 $ -5.56 (-0.91 %)
DIA $ 467.57 $ -0.55 (-0.12 %)
SPY $ 664.46 $ -3.52 (-0.53 %)
TLT $ 89.63 $ 0.26 (0.3 %)
GLD $ 366.82 $ -1.15 (-0.3 %)
$ 10.99
$ 10.96
$ 10.54 x 885
$ 10.55 x 600
$ 10.53 - $ 11.05
$ 9.20 - $ 14.63
4,116,099
na
1.29B
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-02-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-11-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-03-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-08-2017 03-31-2017 10-Q
36 03-13-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-08-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

dynavax-is-providing-fy25-financial-guidance-based-on-its-current-operating-plan-heplisav-b-net-product-revenue-is-expected-in-the-range-of-315m-325m-adjusted-ebitda-is-expected-to-be-at-least-80m-an-increase-compared-to-the-prior-guidance-of-at-least-75m
Dynavax Is Providing FY25 Financial Guidan...
11/05/2025 21:03:57

FULL YEAR 2025 FINANCIAL GUIDANCEDynavax is providing full year 2025 financial guidance, based on its current operating plan: H...

Core News & Articles
Dynavax Technologies Collaborates With Vax...
11/05/2025 21:02:58

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing in...

dynavax-announces-new-100m-share-repurchase-program
Dynavax Announces New $100M Share Repurcha...
11/05/2025 21:02:48

New Share Repurchase ProgramDynavax's Board of Directors authorized the repurchase of up to $100 million of Dynavax's c...

dynavax-technologies-q3-eps-021-beats-012-estimate-sales-94876m-beat-94003m-estimate
Dynavax Technologies Q3 EPS $0.21 Beats $0...
11/05/2025 21:02:06

Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

dynavax-reports-phase-12-data-for-shingles-vaccine-z-1018-begins-head-to-head-trial-vs-shingrix-in-adults-70
Dynavax Reports Phase 1/2 Data For Shingle...
10/21/2025 20:23:24

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly prese...

dynavax-presents-topline-data-from-part-1-of-phase-12-trial-for-shingles-vaccine-candidate-at-idweek-2025-announces-initiation-of-part-2-of-trial
Dynavax Presents Topline Data From Part 1 ...
10/21/2025 20:03:10

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly prese...

robert-f-kennedy-jr-faces-impeachment-push-from-haley-stevens-over-health-care-chaos-and-rising-costs-enough-is-enough
Robert F. Kennedy Jr. Faces Impeachment Pu...
09/26/2025 04:08:24

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secret...

trump-advises-parents-to-split-vaccines-delay-hepatitis-b-shots-until-age-12-this-is-based-on-what-i-feel
Trump Advises Parents To Split Vaccines, D...
09/23/2025 02:32:30

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain imm...

elizabeth-warren-says-measles-can-hit-record-highs-slams-rfk-jrs-cdc-panel-for-delaying-vaccine-how-does-that-keep-our-kids-safe
Elizabeth Warren Says Measles Can Hit Reco...
09/19/2025 02:14:28

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory pa...

jmp-securities-reiterates-market-outperform-on-dynavax-technologies-maintains-32-price-target
JMP Securities Reiterates Market Outperfor...
08/22/2025 12:48:48

JMP Securities analyst Roy Buchanan reiterates Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and maintains $32...

dynavax-says-investigational-shingles-vaccine-at-par-with-gsks-vaccine-in-early-stage-study
Dynavax Says Investigational Shingles Vacc...
08/21/2025 15:46:22

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in olde...

dynavaxs-shingles-vaccine-candidate-z-1018-shows-comparable-immune-response-to-shingrix-with-fewer-side-effects-advancing-to-next-trial-phase-in-2025
Dynavax's Shingles Vaccine Candidate Z-101...
08/21/2025 12:11:09

At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerabi...

jmp-securities-maintains-market-outperform-on-dynavax-technologies-raises-price-target-to-32
JMP Securities Maintains Market Outperform...
08/08/2025 15:35:37

JMP Securities analyst Roy Buchanan maintains Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and raises the pri...

dynavax-technologies-q2-eps-014-beats-009-estimate-sales-91872m-beat-85914m-estimate
Dynavax Technologies Q2 EPS $0.14 Beats $0...
08/07/2025 20:02:02

Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

dynavax-technologies-comments-on-a-report-published-by-glass-lewis--co-says-is-already-delivering-significant-long-term-stockholder-value-through-execution-of-current-strategy-overseen-by-board-deep-tracks-inferior-short-term-plan-and-nominees-are-not-in-the-best-interests-of-all-stockholders
Dynavax Technologies Comments On A Report ...
06/04/2025 21:07:34

deep-track-capital-issues-letter-to-dynavax-technologies-shareholders
Deep Track Capital Issues Letter To Dynava...
05/15/2025 20:03:06

Cites Evidence That the Company is Not Living Up to Its Potential, As Demonstrated By 26% Year-To-Date Share Price Decline, Und...

dynavax-defends-strategic-direction-highlights-vaccine-leadership-and-capital-returns-in-proxy-fight-with-deep-track
Dynavax Defends Strategic Direction, Highl...
05/12/2025 11:36:05

Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director NomineesUrges Stockholders to V...

breaking-down-dynavax-technologies-5-analysts-share-their-views
Breaking Down Dynavax Technologies: 5 Anal...
05/07/2025 21:00:56

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION